Replies to post #1953 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

Is a 1-log decrease going to be sufficient to be a good anti-HBV drug?

These were nuke-suppressed patients, so their viral-load levels for both DNA and RNA were already very low at baseline.

We’ll get a read on the viral-load-reducing efficacy of EDP-514 in the separate trial in viremic patients.

I assume ENTA won't be using EDP-514 as a single drug treatment.

Correct. A three-drug combination is probably going to be necessary for a functional cure. ENTA will eventually test EDP-514 + EDP-721 + nuke, aiming for an all-oral functional cure that no other company is attempting, as far as I know.

I guess we have to see how the 800mg dosage does.

The 400mg and 200mg doses showed good coverage at trough (24-hour) levels, so it’s not clear that 800mg will be better.